BCARE- Real world study on dermatological QoL* in early breast cancer
BCARE : Breast Cancer Adjuvant Real-world of dermatological adverse Events
BCARE is the Europe's first Real World Evidence Study on skin-related quality of life during adjuvant hormone therapy for early breast cancer led by Avene
70% of breast cancer patients remain on hormone therapy for 5 to 10 years*. A long treatment duration, essential for survival... but not without consequences.
Explore the key results of the BCARE study through the infographics below :
*Quality of life
**Hormone dependent cancer. Estimated proportion HR+. World Cancer Research Fund. Global Breast Cancer Statistics. [wcrf.org] »
Interested in our news?
Discover those of our other brands.
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.